(Q72165110)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

title

Perspective on cataractogenic potential of HMG-CoA reductase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

author name string

J S MacDonald

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

publication date

1 January 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

Experimental Eye Research

24 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

page(s)

97-101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

Mechanism of cataract production by 3-β(2-diethylaminoethoxy) androst-5-en-17-one hydrochloride, U18666A: An inhibitor of cholesterol biosynthesis

24 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Preclinical evaluation of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and Simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Clinical experience with lovastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4835%2805%2980087-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-4835(05)80087-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7720809%20AND%20SRC:MED&resulttype=core&format=json

24 October 2019

1 reference